EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析

doi:10.3969/j.issn.1673-8640.2013.06.013

摘要/Abstract

摘要： 目的　利用Meta分析评估表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKIs）一线治疗晚期EGFR突变型非小细胞肺癌（NSCLC）的疗效。方法　在PubMed和Embase文献数据库中检索2004年1月至2012年4月发表的相关文献。制定纳入标准对文献进行筛选以保证纳入研究的同质性。由2名评价者独立评价所纳入研究的质量，提取资料并交叉核对。符合标准的研究采用RevMan5.1软件进行Meta分析。对总有效率（ORR）选择相对危险度（RR）作为效应尺度指标，对无进展生存时间（PFS）和总生存时间（OS）计算风险比（HR），同时计算95%可信区间（CI）。结果　6个Ⅲ期随机对照试验符合全部纳入标准，含1 030例NSCLC患者。Meta分析显示，接受EGFR-TKIs治疗患者与接受化疗的患者相比具有较高的ORR（RR＝2.19，95％CI＝1.68～2.15，P＜0.000 01）和较长的PFS（HR＝0.43，95％CI＝0.35～0.52，P＜0.000 01）；而OS差异无统计学意义（HR＝ 0.98，95％CI＝0.81～1.18，P＝0.80）。结论　EGFR-TKIs一线治疗晚期NSCLC是有效的。为预测一线使用EGFR-TKIs的疗效，应对晚期NSCLC患者进行EGFR基因突变检测。

关键词: 表皮生长因子受体, 突变, 非小细胞肺癌, 酪氨酸激酶抑制剂, Meta分析

Abstract: Objective　To use Meta analysis to evaluate the efficacy of epidermal growth factor receptor（EGFR）- tyrosine kinase inhibitors（TKIs）as first-line treatment for advanced non-small cell lung cancer（NSCLC）with EGFR mutations. Methods　Relevant literatures were searched through PubMed and Embase databases from January 2004 to April 2012. The implement standards for literature-selection were used to ensure the homogeneity of research. Two reviewers evaluated independently the quality of the included studies and extracted the data. Meta analysis was performed by RevMan 5.1 software. Risk ratio（RR）as efficacy index was chosen by overall response rate（ORR），and hazard ratios（HR）were calculated by progression-free survival（PFS）and overall survival（OS）times. The 95% confidence interval（CI）was calculated simultaneously. Results　Six phase Ⅲrandomly controlled trials were included for a total of 1 030 patients with NSCLS. This Meta analysis showed a statistical significance in ORR（RR＝2.19，95% CI＝1.68-2.15，P＜0.000 01）and PFS（HR＝0.43，95%CI＝0.35-0.52，P＜0.000 01）for patients who received EGFR-TKIs compared with patients who received chemotherapy. No statistical significance was observed in OS（HR＝0.98，95%CI＝0.81-1.18，P＝0.80）. Conclusions　EGFR-TKIs are effective as first-line treatment for advanced NSCLC. The EGFR mutation testing should be made for advanced NSCLC patients to predict efficacy to first-line therapy with EGFR-TKIs.

Key words: Epidermal growth factor receptor, Mutation, Non-small cell lung cancer, Tyrosine kinase inhibitor, Meta analysis

张蓉，陈薇雅，甘洁民，赵虎，顾兆祥. EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析[J]. 检验医学, 2013, 28(6): 506-510.

ZHANG Rong，CHEN Weiya，GAN Jiemin，ZHAO Hu，GU Zhaoxiang.. Meta analysis on advanced NSCLC with EGFR mutations treated randomly by EGFR inhibitors[J]. , 2013, 28(6): 506-510.

参考文献

[1]Paez JG，Jänne PA，Lee JC，et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science，2004，304（5676）: 1497-1500.
[2]Lynch TJ，Bell D W，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med，2004，350（21）: 2129-2139.
[3]吴一龙，孙燕，廖美琳，等. EGFR突变型肺癌的处理[J]. 循证医学，2011，11（2）:65-68.
[4]Tierney JF，Stewart LA，Ghersi D，et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials，2007，8:16.
[5]Mok TS，Wu YL，Thongprasert S，et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med，2009，361（10）:947-957.
[6]Fukuoka M，Wu YL，Thongprasert S，et al. Bio-marker analyses and final overall survival results from a phase Ⅲ，randomized，open-label，first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia（IPASS）[J]. J Clin Oncol，2011，29（21）:2866-2874.
[7]Lee JS，Park K，Kim SW，et al. A randomized phase Ⅲ study of gefitinib versus standard chemotherapy（gemcitabine plus cisplatin）as a fi rst-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [J]. J Thorac Oncol，2009，4（suppl）: abstr PRS.4.
[8]Mitsudomi T，Morita S，Yatabe Y，et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）: an open label，randomised phase 3 trial [J]. Lancet Oncol，2010，11（2）:121-128.
[9]Maemondo M，Inoue A，Kobayashi K，et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med，2010，362（25）:2380-2388.
[10]Zhou C，Wu YL，Chen G，et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL，CTONG-0802）: a multicentre，open-label，randomised，phase 3 study[J]. Lancet Oncol，2011，12（8）:735-742.
[11]Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）: a multicentre，open-label，randomised phase 3 trial[J]. Lancet Oncol，2012，13（3）: 239-246.
[12]Douillard JY，Shepherd FA，Hirsh V，et al. Mole-cular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase Ⅲ INTEREST trial[J]. J Clin Oncol，2010，28（5）:744-752.
[13]Maruyama R，Nishiwaki Y，Tamura T，et al. Phase Ⅲ study，V-15-32，of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer[J]. J Clin Oncol，2008，26（26）:4244-4252.
[14]Kim ES，Hirsh V，Mok T，et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer（INTEREST）: a randomised phase Ⅲ trial [J]. Lancet，2008，372（9652）:1809-1818.
[15]Zhu CQ，da Cunha Santos G，Ding K，et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 [J]. J Clin Oncol，2008，26（26）: 4268-4275.
[16]Bell DW，Lynch TJ，Haserlat SM，et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials[J]. J Clin Oncol，2005，23（31）:8081-8092.
[17]Giaccone G，Herbst RS，Manegold C，et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]. J Clin Oncol，2004，22（5）:777-784.
[18]Herbst RS，Giaccone G，Schiller JH，et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]. J Clin Oncol，2004，22（5）: 785-794.
[19]Gatzemeier U，Pluzanska A，Szczesna A，et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial[J]. J Clin Oncol，2007，25（12）:1545-1552.
[20]Cappuzzo F，Ciuleanu T，Stelmakh L，et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre，randomised，placebo-controlled phase 3 study[J]. Lancet Oncol，2010，11（6）: 521-529.
[21]Thatcher N，Chang A，Parikh P，et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised，placebo-controlled，multicentre study（Iressa Survival Evaluation in Lung Cancer）[J]. Lancet，2005，366（9496）:1527-1537.
[22]Hirsch FR，Varella-Garcia M，Bunn PA Jr，et al. Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small-cell lung cancer [J]. J Clin Oncol，2006，24（31）:5034-5042.
[23]麦劲壮，李河，方积乾，等.Meta分析中失安全系数的估计[J].循环医学，2006，6（5）：297-300.
[24]Thongprasert S，Duffield E，Saijo N，et al. Health-related quality-of-life in a randomized phase Ⅲ first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC（IPASS）[J] . J Thorac Oncol，2011，6（11）:1872-1880.
[25]高云，陈嘉昌，朱振宇，等. EGFR基因突变及其检测方法的研究进展[J]. 分子诊断与治疗杂志，2011，14（1）:51-57.
[26]Keedy VL，Temin S，Somerfield MR，et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor（EGFR）mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy [J]. J Clin Oncol，2011，29（15）:2121-2127.